Antibiotics plan for hidradenitis stage 2 flares
Part of Infections, Skin clinical trials.
This Phase 3 study tests whether an adapted antibiotic treatment works better than the standard approach to control hidradenitis suppurativa (HS) symptoms and flares. It may help people with stage 2 HS reduce active inflammation and flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (under 60 years old)
- You have hidradenitis suppurativa (HS) with Hurley stage 2 severity
- You’ve had at least 4 HS flares in the past year and the condition has lasted at least 1 year
- Your BMI is under 35
- You can complete the quality-of-life questionnaire (DLQI) and give written consent
- You have recent blood tests within the last 2 months and can use compatible contraception if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, SAR445399, for people with moderate to severe hidradenitis suppurativa (HS) who haven't improved with oral antibiotics. It aims to see if the drug safely reduces skin bumps and abscesses.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This trial tests a new drug called Brivekimig for people with moderate to severe hidradenitis suppurativa (HS) who have not gotten enough relief from oral antibiotics. The goal is to see if it can reduce abscesses and inflamed bumps.
This study tests a new medicine called LAD191 for people with moderate to severe hidradenitis suppurativa (HS) who haven't been helped enough by antibiotics. Researchers want to see if LAD191 safely reduces painful bumps and tunnels.
This trial tests whether taking capsules containing healthy gut bacteria (fecal microbiota transplant) can help treat hidradenitis suppurativa. You may qualify if you have HS and haven't taken antibiotics in the last 30 days.
This study tracks how secukinumab (a new medication) works for hidradenitis suppurativa—a painful skin condition with recurring boils and abscesses—in real-world patient care in Italy. Researchers want to understand treatment patterns and outcomes to help improve care for this condition.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.